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Background: There have been no previous reports that apolipoprotein (apo) A-I mimetic peptide improves
survival rate after myocardial infarction (MI).
Method and results:Male C57Bl/6J mice were subjected to left coronary artery permanent ligation as a model of
MI.We synthesized a novel 24-amino acid apoA-Imimetic peptide-type5 (FAMP5),which potently removes cho-
lesterol via speciﬁc ATP-binding cassette transporter A1 (ABCA1). FAMP5was associatedwith a signiﬁcantly im-
proved survival rate by protecting against cardiac rupture compared to the control. mRNA levels for eNOS, Gata-
4, CTGF and ANP were signiﬁcantly increased in the hearts of the FAMP5-treated group, while that for MCP-1
decreased.
Conclusion: This is theﬁrst report that high-density lipoprotein (HDL) therapywith FAMP5 improved the survival
rate after MI.
©2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Percutaneous coronary intervention (PCI) has dramatically improved
the short-term survival rate after myocardial infarction (MI) over the
past two decades. Despite the fact that patients have beneﬁted from
the use of PCI after MI, the incidence of myocardial rupture has not
decreased [1,2]. We synthesized a novel 24-amino acid apoA-I mimetic
peptide without phospholipids, known as Fukuoka University apoA-I
Mimetic Peptide (FAMP) of inducible cholesterol efﬂux (iCE) peptide,
which potently removes cholesterol in vitro via ABCA1 [3,4], in addition
to its endothelial-protecting, anti-oxidation, and anti-inﬂammation
action [5,6]. While high-density lipoprotein (HDL) has been shown to
have pleiotropic effects against cardiac events, it is still remaining unclear
whether apoA-I mimetics can inﬂuence a hard endpoint and the survival
rate after MI.y, Fukuoka University School of
, saku-k@fukuoka-u.ac.jp
to this work.
land Ltd. This is an open access article2. Methods
Eight- to 10-week-oldmale C57Bl/6Jmicewere subjected to left ante-
rior coronary artery permanent ligation by 6-0 silk suture for 1 week as
an experimental model of MI. Twenty-four hours later, we assigned the
animals into 3 groups. Control mice were injected intraperitoneally
(i.p.) with 300 μl of PBS on 1, 3 and 5 days post operation. Type 5 of
FAMP (FAMP5) was injected i.p. at 10 mg/kg (FAMP5-L as low dose-
FAMP5) or 50 mg/kg (FAMP5-H as high dose-FAMP5) on 1, 3 and 5
days post operation. The experiments complied with the regulations
of the Committee on Ethics in the Care and Use of Laboratory Animals.
All results are expressed as the mean ± standard deviation (SD) and
p values b0.05 were considered to be statistically signiﬁcant.2.1. Synthesize of FAMP5
Thedesign of the FukuokaUniversity apoA-IMimetic Peptide (FAMP)
is based upon the general structure of the amphipathic α-helical repeats
in apoA-I with its separation of polar and nonpolar residues on the two
faces of the helix and distribution of charged residues. FAMP (FAMP5:
H-ALEHLFTLYEKALKALEDLLKKLL-OH), was synthesized by Fmoc (N-[9-
ﬂuorenyl] methoxycarbonyl)-based solid-phase peptide synthesis
using an automated peptide synthesizer, Pioneer and Model 433A, from
Applied Biosystems, Inc.under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Control (n=7) FAMP5 -L(n=8) FAMP5-H(n=8)
HR (beat/min) 530 ± 23 556 ± 33 563 ± 22
SBP (mmHg) 84 ± 9 86 ± 6 84 ± 10
DBP (mmHg) 51 ± 2 50 ± 5 46 ± 3
MBP (mmHg) 34 ± 2 32 ± 2 29 ± 4
TC (mg/dl) 77 ± 22 83 ± 19 78 ± 16
HDL-C (mg/dl) 30 ± 6 30 ± 4 28 ± 2
Infarct size (%) 45 ± 5 46 ± 6 48 ± 4
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Fig. 1.A. Lipoprotein proﬁles and hemodynamics. B. Survival rate afterMI. *pb 0.05 vs. control group, by theCochran–Armitage test. C.mRNA expression, (a) to (e), in themouse heart after
MI. Comparisons were made by ANOVA followed by Tukey's test.
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There was no difference in the lipid proﬁle after treatment with
FAMP5. Hemodynamic parameters and LV infarct size were also similar
in the 3 groups (Fig. 1-A). However, the survival rate during the acute
phase after MI in the FAMP5-H group (8/9, 89%) was much better
than those in the FAMP5-L (8/11, 73%) and control (7/13, 54%) groups.
Interestingly, we could ﬁnd that in all cases of death after MI, except for
one mouse in the FAMP5-L group, the cause of death was cardiac
rupture (Fig. 1-B). We then evaluated mRNA expression in the heart.
FAMP5-H showed signiﬁcant reductions in MCP-1 mRNA levels, and a
trend was seen in the FAMP5-L group. In addition, mRNA levels of an-
giogenic compounds (eNOS, Gata-4) were signiﬁcantly up-regulated
by FAMP5-L, and a trend was seen in the FAMP5-H group. CTGF and
ANP were signiﬁcantly up-regulated in both the FAMP5-H and
FAMP5-L groups.
4. Discussion
The novel ﬁnding in this study is that FAMP5 signiﬁcantly improved
the survival rate afterMI, particularly by preventing cardiac rupture. Not
only did FAMP5 change the hemodynamics, but also infarct size was
identical in ourmodels. In addition, FAMP5 did not alter the lipid proﬁle
at all, even at a high dose. Coronary events have not been adequately
prevented by statins, and therapeutic options for increasing HDL func-
tionality have stepped into the spotlight, albeit little progress has been
made. The use of an apoA-I mimetic peptide is much simpler fortherapeutic purposes than increasing the mass of HDL or apoA-I.
FAMP5 was associated with changes in mRNA levels of eNOS, Gata-4,
ANP, MCP-1 and CTGF (Fig. 1-C), and CTGF was previously reported as
one of the main factors related to cardiac rupture after MI [7]. It has
been reported that FAMP5 improved atherosclerotic lesion through a
suppressed inﬂammation and enhanced HDL function [3]. These results
suggest that FAMP5might play a role inmaintainingheartmuscle struc-
ture after acute myocardial infarction. Myocardial infarction that trig-
gers a robust inﬂammatory response, which is essential for cardiac
repair, is also involved in the pathogenesis of remodeling subsequently
heart failure. In conclusion, these results indicate that our FAMP5 might
prevent cardiac rupture, which improves the survival rate in the acute
phase after MI, through anti-inﬂammatory and vasculoangiogenic effects
in the heart, i.e., by raising HDL-functionality.Conﬂict of interest
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